Dermapharm Holding SE
Dermapharm Holding EU Taxonomy Data Preview
In 2024, Dermapharm Holding was subject to the Corporate Sustainability Reporting Directive (CSRD)'s requirements, which mandated the company to publish EU Taxonomy disclosures.
The company reported the eligibility and alignment of Turnover, Capital Expenditure (CAPEX) and Operating Expenditure (OPEX) with the EU Taxonomy, helping assess the extent to which its business activities align with Europe's environmental sustainability goals.
Dermapharm Holding has also provided an activity-level breakdown of its EU Taxonomy disclosures. This granular reporting enhances transparency around which economic activities of Dermapharm Holding are considered environmentally sustainable and contribute to at least one of the six environmental objectives defined under the EU Taxonomy framework.
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Taxonomy Aligned A1 Turnover | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Eligible A Turnover | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Non-Eligible B Turnover | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Taxonomy Aligned A1 Opex | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Taxonomy Eligible A Opex | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Non-Eligible B Opex | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Taxonomy Aligned A1 Capex | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Taxonomy Eligible A Capex | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Taxonomy Non-Eligible B Capex | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected EU Taxonomy data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Dermapharm Holding's Revenues from Sustainable Activities
In 2024, Dermapharm Holding reported EU Taxonomy-eligible revenues of EUR 608.20 million, representing 51.5% of its total turnover. Of this amount, EUR 0 of Dermapharm Holding's revenues was classified as EU Taxonomy-aligned, indicating that 0% of the revenue-generating activities undertaken by the company substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).
Insights into Dermapharm Holding's CAPEX from Sustainable Activities
In 2024, Dermapharm Holding reported EU Taxonomy-eligible CAPEX of EUR 27.30 million, representing 61.2% of its total CAPEX. Of this amount, EUR 0 of Dermapharm Holding's CAPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's investments were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).
Dermapharm Holding's Taxonomy-Eligible Capex Over Time
- Total Taxonomy Aligned A1 Capex
- Total Taxonomy Eligible but Not Aligned A2 Capex
Have Dermapharm Holding's increased its investment in sustainable activities over time?
Since 2022, Dermapharm Holding's taxonomy-aligned capital expenditure (CAPEX) decreased by 100%, indicating a long-term decline in green capital deployment, potentially signaling shifting priorities or reduced focus on sustainability-linked investments.
Insights into Dermapharm Holding's OPEX from Sustainable Activities
In 2024, Dermapharm Holding reported EU Taxonomy-eligible OPEX of EUR 23.50 million, representing 70.1% of its total operating expenses (OPEX). Of this amount, EUR 0 of Dermapharm Holding's OPEX was classified as EU Taxonomy-aligned, indicating that 0% of the company's operating expenses were directed toward economic activities that substantially contribute to one or more of the six environmental objectives, meet the Do No Significant Harm (DNSH) criteria, and comply with the Minimum Social Safeguards (MSS).
Dermapharm Holding's Taxonomy-Eligible Opex Over Time
- Total Taxonomy Aligned A1 Opex
- Total Taxonomy Eligible but Not Aligned A2 Opex
Have Dermapharm Holding's increased its spending in sustainable activities over time?
Since 2022, Dermapharm Holding's taxonomy-aligned operating expenditure (OPEX) decreased by 100%, indicating a long-term decline in sustainability-related operational spending, which may reflect shifting priorities or reduced emphasis on green initiatives.